1. Home
  2. AXDX vs PHGE Comparison

AXDX vs PHGE Comparison

Compare AXDX & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXDX
  • PHGE
  • Stock Information
  • Founded
  • AXDX 1982
  • PHGE 2015
  • Country
  • AXDX United States
  • PHGE Israel
  • Employees
  • AXDX N/A
  • PHGE N/A
  • Industry
  • AXDX Biotechnology: Laboratory Analytical Instruments
  • PHGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • AXDX Industrials
  • PHGE Health Care
  • Exchange
  • AXDX Nasdaq
  • PHGE Nasdaq
  • Market Cap
  • AXDX 13.7M
  • PHGE 14.6M
  • IPO Year
  • AXDX 1996
  • PHGE N/A
  • Fundamental
  • Price
  • AXDX $0.03
  • PHGE $0.56
  • Analyst Decision
  • AXDX
  • PHGE Strong Buy
  • Analyst Count
  • AXDX 0
  • PHGE 2
  • Target Price
  • AXDX N/A
  • PHGE $23.00
  • AVG Volume (30 Days)
  • AXDX 2.5M
  • PHGE 59.0K
  • Earning Date
  • AXDX 05-20-2025
  • PHGE 05-15-2025
  • Dividend Yield
  • AXDX N/A
  • PHGE N/A
  • EPS Growth
  • AXDX N/A
  • PHGE N/A
  • EPS
  • AXDX N/A
  • PHGE N/A
  • Revenue
  • AXDX $11,698,000.00
  • PHGE N/A
  • Revenue This Year
  • AXDX $7.25
  • PHGE N/A
  • Revenue Next Year
  • AXDX N/A
  • PHGE N/A
  • P/E Ratio
  • AXDX N/A
  • PHGE N/A
  • Revenue Growth
  • AXDX N/A
  • PHGE N/A
  • 52 Week Low
  • AXDX $0.12
  • PHGE $0.48
  • 52 Week High
  • AXDX $2.09
  • PHGE $4.99
  • Technical
  • Relative Strength Index (RSI)
  • AXDX 13.15
  • PHGE 47.20
  • Support Level
  • AXDX $0.12
  • PHGE $0.50
  • Resistance Level
  • AXDX $0.56
  • PHGE $0.59
  • Average True Range (ATR)
  • AXDX 0.05
  • PHGE 0.04
  • MACD
  • AXDX -0.04
  • PHGE -0.00
  • Stochastic Oscillator
  • AXDX 0.00
  • PHGE 42.73

About AXDX Accelerate Diagnostics Inc.

Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: